Candel Therapeutics (CADL) Income towards Parent Company (2020 - 2023)
Historic Income towards Parent Company for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$5.4 million.
- Candel Therapeutics' Income towards Parent Company rose 3160.63% to -$5.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$33.7 million, marking a year-over-year increase of 424.87%. This contributed to the annual value of -$30.2 million for FY2024, which is 1044.05% up from last year.
- Latest data reveals that Candel Therapeutics reported Income towards Parent Company of -$5.4 million as of Q4 2023, which was up 3160.63% from -$9.0 million recorded in Q3 2023.
- In the past 5 years, Candel Therapeutics' Income towards Parent Company ranged from a high of -$2.5 million in Q2 2020 and a low of -$9.8 million during Q2 2023
- Its 4-year average for Income towards Parent Company is -$7.1 million, with a median of -$7.9 million in 2022.
- Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 19700.89% in 2021, then surged by 3160.63% in 2023.
- Quarter analysis of 4 years shows Candel Therapeutics' Income towards Parent Company stood at -$6.1 million in 2020, then decreased by 27.57% to -$7.8 million in 2021, then fell by 1.6% to -$7.9 million in 2022, then skyrocketed by 31.61% to -$5.4 million in 2023.
- Its last three reported values are -$5.4 million in Q4 2023, -$9.0 million for Q3 2023, and -$9.8 million during Q2 2023.